Pay in 4 interest-free payments of $5.62 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
In the trial of obesity without diabetes, or SYNCHRONIZE-1, Survodutide achieved a primary outcome endpoint of 16.6% weight reduction in that highest dose group in those on treatment
This is truly preventative medicine
Comparative Efficacy and Safety of Different Orforglipron Doses in Patients With Type 2 Diabetes Mellitus and Obesity: A Systematic Review and Network Meta-Analysis
11.5.3 Adjusts interventions based on client/patient progress in meeting established goals and resolving nutrition diagnoses
Backed by research
Gerken T, Girard CA, Tung YC, Webby CJ, Saudek V, Hewitson KS, et al
US$ 26.24
US$ 25.29
US$ 22.26
US$ 22.61
US$ 29.80
US$ 25.01
